Vizient has ranked Rush University Medical Center #1 for quality among the nation’s most prestigious academic medical centers. Learn more.

Excellence is just the beginning.

Translate

French German Italian Portuguese Russian

Treatment Study for Patients With Soft Tissue Sarcoma

Clinical Trial Title: 
A phase Ib trial of neoadjuvant AMG 232 concurrent with preoperative radiotherapy in wild-type P53 soft tissue sarcoma (STS).
Clinical Trial Protocol ID: 
18010902
Clinical Trial Investigator Name: 
Dian Wang, MD, PhD
Clinical Trial Protocol Description: 

This phase Ib trial studies the side effects of MDM2 inhibitor AMG-232 and radiation therapy in treating patients with soft tissue sarcoma. MDM2 inhibitor AMG-232 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving MDM2 inhibitor AMG-232 and radiation therapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed.

Clinical Trial Eligibility Criteria: 

In order to participate you must meet the following criteria:

  • Have pathologically proven diagnosis of grade 2-3 (intermediate or high grade) soft tissue sarcoma.
  • Have a planned definitive surgical resection of the primary tumor.
  • Have an Eastern Cooperative Oncology Group (ECOG) or Zubrod performance status of 0-1 within 30 days prior to registration.

This is a partial list of inclusion and exclusion criteria.

Clinical Trial Area: 
Sarcomas
Contact Phone: 
(312) 942-8892
Contact Name: 
Jean Gibson, RN